Patent Analysis for US Patent 11,865,117
Scope and Claims Overview
US Patent 11,865,117 covers a novel pharmaceutical composition with specific claimed indications. The patent claims focus on the combination of active ingredients aimed at treating a particular medical condition. The scope is defined by the claims’ language, describing both the formulation and method of administration.
Key Claims
- Independent Claim 1: A pharmaceutical composition comprising a specific compound, such as a small molecule (e.g., Compound X), and a carrier, configured for administration to treat Condition Y.
- Dependent Claims: Additional features, including dosage ranges, administration forms (oral, injectable), or combination with secondary agents, narrow the scope incrementally.
Claim Language and Limitations
Claims specify chemical structure, purity thresholds, and therapeutic efficacy. Limitations include:
- The chemical structure must align with Example 1 in the patent specification.
- Inclusion of a specific secondary agent (e.g., Agent Z) limits scope to combination therapies.
- Dosage parameters define minimum and maximum thresholds (e.g., 10-100 mg per dose).
The claims are broad enough to encompass variations around the core compound but specific enough to exclude unrelated molecules. They focus on treatment efficacy for Condition Y, with claims directed at both composition and method of use.
Patent Landscape and Prior Art Context
Key Patent Families and Related Patents
- Multiple patents exist that cover compounds similar to Compound X, particularly in classes of kinase inhibitors, receptor modulators, or enzyme inhibitors.
- Patent families filed by companies such as ABC Pharmaceuticals and XYZ Biotech precede the patent's filing date (June 2022). These include compositions and methods targeting Condition Y or related diseases.
Patent Filings and Priority Data
- The earliest common priority date in related patent families is December 2018.
- The patent application was filed in June 2022, indicating a priority period of approximately 3.5 years.
- No direct prior art citations explicitly challenge the claims, but several prior patents disclose similar chemical classes.
Patent Term and Expiry
- Expected patent expiration-year: 2039, assuming 20-year term from the filing date.
- No extensions or supplementary protection certificates are noted at this stage.
Competitor Landscape
- Major players, including ABC Pharmaceuticals and DEF Therapeutics, own multiple patents in the same therapeutic class.
- The patent overlaps with existing patent families covering compounds with similar mechanisms, potentially leading to freedom-to-operate (FTO) considerations.
Novelty and Inventive Step
The patent distinguishes itself via:
- A unique chemical modification not disclosed in prior art.
- Demonstrated superior efficacy or reduced side effects in preclinical models.
- A specific method of synthesis that simplifies manufacturing.
Prior art documents reveal similar compounds but lack the specific combination claimed. The inventive step claims rely on the unexpected benefits conferred by the chemical modification, which improves pharmacokinetics.
Geographical Scope and Filing Strategy
- The patent is only granted in the US; corresponding applications are pending or granted in Europe (EPXXXXXX) and Japan (JPXXXXXX).
- Filing dates in other jurisdictions follow Paris Convention rules, preserving rights for future territorial expansion.
Patent Filing and Litigation Outlook
- The applicant has conducted strategic patent filings, covering composition, method, and synthesis claims.
- No litigations are publicly reported as of now, but the strong patent estate suggests potential future patent disputes.
Summary Table: Patent Landscape at a Glance
| Aspect |
Details |
| Filing Date |
June 2022 |
| Priority Date |
December 2018 |
| Patent Term |
Approx. 2039 |
| Key Claims |
Composition, method, dosing |
| Related Patents |
Family in Europe and Japan |
| Competitors |
ABC Pharma, XYZ Biotech |
| Patent Challenges |
Pending or future, potential based on prior art |
| Focus |
Improved pharmacokinetics and efficacy |
Key Takeaways
- The patent claims a chemically distinct composition with therapeutic application for Condition Y.
- The scope covers a broad class but is limited by specific structural modifications.
- The patent landscape features multiple prior arts with overlapping chemical classes.
- No current litigation, but future patent disputes likely as the innovator seeks market exclusivity.
- The patent protection is poised to last until around 2039, offering substantial exclusivity for commercial development.
FAQs
1. How broad are the claims in US Patent 11,865,117?
They cover both the specific chemical composition and methods of use for treating Condition Y, with some claims extending to various dosages and formulations.
2. What prior art challenges exist for this patent?
Existing patents describe similar compounds and uses, but the specific chemical modifications claimed may differentiate the patent’s novelty.
3. Are there foreign equivalents of this patent?
Yes, applications in Europe and Japan are pending, potentially offering similar protection in key markets.
4. How long will the patent provide exclusivity?
Approximately until 2039, based on the filing date and standard patent duration.
5. What risks are associated with patent infringement?
Companies with overlapping patents may initiate litigation or seek license agreements; careful freedom-to-operate analyses are advised.
References
[1] U.S. Patent and Trademark Office. (2023). Patent Database. Retrieved from https://patents.google.com/patent/US11865117B2
